SLU-PP-332 vs Pentapeptide-18
Side-by-side comparison of key properties, dosing, and research.
Recovery & RepairFat Loss & Metabolic
SLU-PP-332Skin & CosmeticAnti-Aging & Longevity
Pentapeptide-18- Summary
- SLU-PP-332 is a small molecule exercise mimetic that activates estrogen-related receptors ERRalpha and ERRdelta (ERRa/d), transcription factors that drive oxidative metabolism programs. In animal studies it significantly enhanced endurance capacity and metabolic fitness without exercise, mimicking many of the cardiovascular and metabolic adaptations of aerobic training.
- Pentapeptide-18 (Leuphasyl) is a synthetic pentapeptide that mimics the sequence of enkephalin, an endogenous neuropeptide. It acts on neuronal pain receptors in facial muscles to reduce muscle contraction intensity and depth of expression lines, functioning similarly to Argireline (Acetyl Hexapeptide-3) but via a different receptor mechanism.
- Half-Life
- Not established in humans; rodent pharmacokinetics suggest hours
- Not applicable (topical)
- Admin Route
- Oral (research), Subcutaneous (research)
- Topical
- Research
- —
- —
- Typical Dose
- Not established for humans; rodent studies used ~100 mg/kg/day
- 0.005–0.05% in formulation
- Frequency
- Once daily in rodent studies
- Twice daily
- Key Benefits
- Significant enhancement of aerobic endurance capacity
- Increases mitochondrial density and oxidative metabolism in muscle
- Promotes beneficial shift toward oxidative muscle fiber phenotype
- Improves cardiac efficiency and cardiovascular fitness markers
- Potential for obesity, metabolic syndrome, and heart failure treatment
- Exercise mimetic for populations unable to exercise (disability, frailty, disease)
- Reduces depth of expression lines (forehead, crow's feet, glabellar)
- Inhibits acetylcholine release for muscle-relaxing effect
- Complementary mechanism to Argireline for enhanced anti-wrinkle activity
- Reversible and well-tolerated
- No risk of systemic paralysis at cosmetic concentrations
- Suitable for daily use in serums and creams
- Side Effects
- Limited human data; all studies are preclinical (rodent)
- Unknown cardiovascular effects with long-term or high-dose use in humans
- Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
- Off-target effects not fully characterized
- Generally very well-tolerated topically
- Rare skin sensitivity or mild irritation
- Theoretical opioid receptor desensitization with very prolonged high-dose use (not documented cosmetically)
- Stacks With
- —
- —